195 related articles for article (PubMed ID: 24750786)
1. Glioblastoma stem cells: a new target for metformin and arsenic trioxide.
Carmignani M; Volpe AR; Aldea M; Soritau O; Irimie A; Florian IS; Tomuleasa C; Baritchii A; Petrushev B; Crisan G; Valle G
J Biol Regul Homeost Agents; 2014; 28(1):1-15. PubMed ID: 24750786
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
3. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Ling S; Xie H; Yang F; Shan Q; Dai H; Zhuo J; Wei X; Song P; Zhou L; Xu X; Zheng S
J Hematol Oncol; 2017 Feb; 10(1):59. PubMed ID: 28241849
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide regulates the apoptosis of glioma cell and glioma stem cell via down-regulation of stem cell marker Sox2.
Sun H; Zhang S
Biochem Biophys Res Commun; 2011 Jul; 410(3):692-7. PubMed ID: 21703238
[TBL] [Abstract][Full Text] [Related]
5. Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation.
Leidgens V; Proske J; Rauer L; Moeckel S; Renner K; Bogdahn U; Riemenschneider MJ; Proescholdt M; Vollmann-Zwerenz A; Hau P; Seliger C
Oncotarget; 2017 Jan; 8(5):8250-8263. PubMed ID: 28030813
[TBL] [Abstract][Full Text] [Related]
6. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
7. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
8. Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK.
Sato A; Sunayama J; Okada M; Watanabe E; Seino S; Shibuya K; Suzuki K; Narita Y; Shibui S; Kayama T; Kitanaka C
Stem Cells Transl Med; 2012 Nov; 1(11):811-24. PubMed ID: 23197693
[TBL] [Abstract][Full Text] [Related]
9. The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma.
Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Tumour Biol; 2014 May; 35(5):4567-80. PubMed ID: 24399651
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme.
Tomuleasa C; Soritau O; Kacso G; Fischer-Fodor E; Cocis A; Ioani H; Timis T; Petrescu M; Cernea D; Virag P; Irimie A; Florian IS
J BUON; 2010; 15(4):758-62. PubMed ID: 21229642
[TBL] [Abstract][Full Text] [Related]
11. 2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways.
Estañ MC; Calviño E; de Blas E; Boyano-Adánez Mdel C; Mena ML; Gómez-Gómez M; Rial E; Aller P
Biochem Pharmacol; 2012 Dec; 84(12):1604-16. PubMed ID: 23041229
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway.
Wu J; Ji Z; Liu H; Liu Y; Han D; Shi C; Shi C; Wang C; Yang G; Chen X; Shen C; Li H; Bi Y; Zhang D; Zhao S
Toxicol Lett; 2013 Jun; 220(1):61-9. PubMed ID: 23542114
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of arsenic trioxide in transformed human thyroid cells.
Fröhlich E; Czarnocka B; Brossart P; Wahl R
Thyroid; 2008 Nov; 18(11):1183-93. PubMed ID: 19014326
[TBL] [Abstract][Full Text] [Related]
14. Characterization of arsenic trioxide resistant clones derived from Jurkat leukemia T cell line: focus on PI3K/Akt signaling pathway.
Roszak J; Smok-Pieniążek A; Nocuń M; Stępnik M
Chem Biol Interact; 2013 Oct; 205(3):198-211. PubMed ID: 23911876
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of arsenic trioxide on retinoblastoma: cell differentiation and apoptosis depending on arsenic trioxide concentration.
Kim JH; Kim JH; Yu YS; Kim DH; Kim CJ; Kim KW
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1819-23. PubMed ID: 19060284
[TBL] [Abstract][Full Text] [Related]
16. Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.
Calviño E; Estañ MC; Simón GP; Sancho P; Boyano-Adánez Mdel C; de Blas E; Bréard J; Aller P
Biochem Pharmacol; 2011 Dec; 82(11):1619-29. PubMed ID: 21889928
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide sensitizes glioblastoma to a myc inhibitor.
Yoshimura Y; Shiino A; Muraki K; Fukami T; Yamada S; Satow T; Fukuda M; Saiki M; Hojo M; Miyamoto S; Onishi N; Saya H; Inubushi T; Nozaki K; Tanigaki K
PLoS One; 2015; 10(6):e0128288. PubMed ID: 26038891
[TBL] [Abstract][Full Text] [Related]
18. Arsenic Trioxide Induces Apoptosis and Incapacitates Proliferation and Invasive Properties of U87MG Glioblastoma Cells through a Possible NF-κB-Mediated Mechanism.
Ghaffari SH; Yousefi M; Dizaji MZ; Momeny M; Bashash D; Zekri A; Alimoghaddam K; Ghavamzadeh A
Asian Pac J Cancer Prev; 2016; 17(3):1553-64. PubMed ID: 27039805
[TBL] [Abstract][Full Text] [Related]
19. Novel human neutrophil agonistic properties of arsenic trioxide: involvement of p38 mitogen-activated protein kinase and/or c-jun NH2-terminal MAPK but not extracellular signal-regulated kinases-1/2.
Binet F; Girard D
J Leukoc Biol; 2008 Dec; 84(6):1613-22. PubMed ID: 18728151
[TBL] [Abstract][Full Text] [Related]
20. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
